<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191208045652N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-18</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of TECAR therapy and neurodynamic techniques in treatment of carpal tunnel syndrome.</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of TECAR therapy and neurodynamic techniques VS. neurodynamic techniques and placebo TECAR on pain and function in subjects with carpal tunnel syndrome.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52902</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, a simple randomization method is used.Randomization tool is also a software for random sequence production (software allocation Random).A set of random numbers is given by the software and before starting the study, it is determined that the intervention group of even numbers is assigned to the control group of odd numbers.
Concealment Allocation is used for hiding, Which refers to the method used to execute a random sequence on study participants, in such a way that the assigned group is not known before the individual is assigned.Using opaque envelopes sealed in random sequence in this method, each of the random sequences created is recorded on a card and the cards are placed in the envelopes of the letter, respectively.In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface.Finally, the lids of the letter envelopes are glued and placed inside a box, respectively.
At the time of registration of participants, based on the order in which eligible participants enter the study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed, Blinding description: Evaluation and treatment are performed by two people.The person evaluating and analyzing the data are those who do not know about grouping. The evaluator is present in the research only at the time of evaluation (before and after treatment).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Carpal Tunnel Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: In this study, TECAR (winback made in France) is used. The frequency used is 300 kHz which is selected due to the use of metal electrodes and the lack of high heat and burns. The patient is asked to sit on a chair and put their hand in supine position comfortably on a table in front of them. Current is applied to the transverse ligament of the wrist for 20 minutes using a resistance electrode with gel. The counter electrode is placed on the dorsal surface of the wrist. Treatment is done in 5 sessions and 2 times a week. In order to perform the neurodynamic technique of the median nerve, the patient is first asked to lie in supine position on the treatment bed. The therapist is then placed next to the bed and the patient's shoulder is taken to the depression. Meanwhile, the arm is placed in abduction and external rotation. In the next step, the forearm is taken to supination. Finally, while the patient's elbow is flexed, the wrists and fingers are extended Then, by extending the patient's elbow, therapist flex the wrists and fingers. The speed and intensity of the movement should be such that it does not cause pain to the patient. Treatment is done in 5 sessions 2 times a week. The technique is applied in each session in 3 sets of 60 with a 30 second interval between each set. Intervention 2: Control group: placebo TECAR with neurodynamic techniques, Placebo TECAR is applied by the therapist to the transverse ligament of the wrist. All of the parameters similar to the treatment group, are performed on the transverse ligament of the wrist for 20 minutes but TECAR is silent. After the TECAR therapy the neurodynamic technique of median nerve slippage is performed.  A total of 6 sessions of treatment are performed. Each session is 60 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after identifying individuals.

When:
6 months after printing the results

To whom:
The information is available to all researchers working in academic and scientific institutions.

Conditions:
It is possible only by mentioning the name and organizational affiliation of the executor and colleagues of the project.

Where to obtain:
M.yassin.pt@gmail.com

How to obtain:
If the data is used in scientific and therapeutic activities, the information is provided to individuals as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyyede Elnaz Hashemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mirdamad, Mother Square, Nezam Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15459-13487</zip>
        <telephone>+98 21 2222 2059</telephone>
        <email>eli.hshmi@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Marzieh Yassin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasool Akram Hospital, Sattar Khan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>091222222508</telephone>
        <email>m.yassin.pt@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with age range of 18-60 years ol
Pain and paresthesia in at least 2 fingers of 3/5 lateral fingers for 1-6 months.
Diagnosis of CTS based on EMG tests (distal motor latency&gt;4m.s and distal sensory latency &gt;5/3 m.s)
Positive Phalen and Tinel test
Ability to read and write in Persian</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>pregnancy
Thenar atrophy
history of any hand or wrist surgery
Metabolic diseases (Diabetes mellitus, thyroid or kidney problem)
cervical radiculopathy
Fibromyalgia or other musculoskeletal disorders
Any history of severe trauma to the wrist and Connective tissue disorders
Patient dissatisfaction with the continuation of the treatment and evaluation process</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In this study, TECAR (winback made in France) is used. The frequency used is 300 kHz which is selected due to the use of metal electrodes and the lack of high heat and burns. The patient is asked to sit on a chair and put their hand in supine position comfortably on a table in front of them. Current is applied to the transverse ligament of the wrist for 20 minutes using a resistance electrode with gel. The counter electrode is placed on the dorsal surface of the wrist. Treatment is done in 5 sessions and 2 times a week. In order to perform the neurodynamic technique of the median nerve, the patient is first asked to lie in supine position on the treatment bed. The therapist is then placed next to the bed and the patient's shoulder is taken to the depression. Meanwhile, the arm is placed in abduction and external rotation. In the next step, the forearm is taken to supination. Finally, while the patient's elbow is flexed, the wrists and fingers are extended Then, by extending the patient's elbow, therapist flex the wrists and fingers. The speed and intensity of the movement should be such that it does not cause pain to the patient. Treatment is done in 5 sessions 2 times a week. The technique is applied in each session in 3 sets of 60 with a 30 second interval between each set.</i_keyword>
      <i_keyword>Control group: placebo TECAR with neurodynamic techniques, Placebo TECAR is applied by the therapist to the transverse ligament of the wrist. All of the parameters similar to the treatment group, are performed on the transverse ligament of the wrist for 20 minutes but TECAR is silent. After the TECAR therapy the neurodynamic technique of median nerve slippage is performed.  A total of 6 sessions of treatment are performed. Each session is 60 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: At the beginning and the end of each session and two months after the end of the last treatment session. Method of measurement: visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Grip strength. Timepoint: At the beginning and the end of each session and two months after the end of the last treatment session. Method of measurement: Hand held dynamo meter.</sec_outcome>
      <sec_outcome>Functional status scale of Boston questionnaire. Timepoint: Before treatment, at the end of third session and two months after the end of the last treatment session. Method of measurement: Persian Boston Questionnaire.</sec_outcome>
      <sec_outcome>Symptom severity scale of Boston Questionnaire. Timepoint: Before treatment, at the end of third session and two months after the end of the last treatment session. Method of measurement: Persian Boston Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-06</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Nezam Ave, Madar Blvd, Mirdamad Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
